A mini report identifying drivers and barriers to sustaining financial performance over the next 5 years for the top five global pharmaceutical companies Johnson & Johnson, Pfizer, GSK, Novartis and Sanofi-Aventis
This report presents the cases of the top five global pharma companies: J&J, Pfizer, GSK, Novartis and Sanofi-Aventis and identifies their key growth areas. Pooling data from 6 major investment institutions, it delivers a 360-degree analysis on these big five global pharma with further value add and refinement coming from 8 leading key opinion leaders, to produce an easy to read 25 page PowerPoint deck.
Johnson & Johnson has reached a critical point in its product portfolio which should see the company convert from “cash cow” (high market share; low market growth) to “star” (high market share; high market growth) status by 2010. This is reflected in J&J having not less than 6 late-stage drugs that will either unveil phase III data or be filed with the FDA within 2008 culminating in a strong impact on its P&L account by 2010.
Likewise, the other cash cow Pfizer, boasts of at least 17 disclosed products under late phase development, with launches in the post-2010 period, thus are likely to buoy double-digit sales growth beyond Lipitor patent expiry.
GlaxoSmithKline on the other hand, has a product portfolio with a significant cash flow position this, in turn, has spurred on a meaningful gearing by GSK management. This puts the company firmly in a star performing position for 2008-2011. With asset consolidation of $23.5bn USD over three years post-2009, the company is likely to attain double-digit earnings growth out to 2011 with mid-digit growth in 2012 impacted by generic competition.
In the same star category is Novartis with top-line growth driven by a combination of solid cash-generating franchises (Diovan, Gleevec) revealing steady growth and an extensive and rich research pipeline with the potential to generate as many as 4-6 new filings per the year 2008-2011.
Sanofi-Aventis’ strong 2008 second quarter performance qualifies the company as a star company however this status is likely to come under threat; key impacts are from the risk of generic Plavix during 2008-2011 and high investment phase III projects lacking in validated data with pivotal results for Acomplia, for example, awaiting on CRESCENDO study results not scheduled for release until 2010, thus potentially sliding the company into “question mark” (low market share; high market growth) status.
Analysis of “buys” on the basis of EPS growth rates against market peers reveals, GlaxoSmithKline (14% against EU rate of 8%) and Johnson & Johnson (14% against US peer rate of 9%) are preferred over the three other companies researched.
PEG ratios between 1 and 2 are considered to be in the range of normal values for pharma. Pooled analysis suggests that companies with PEG values between 0 to 1 may provide higher returns and so the decreasing order of returns is: GSK (0.98), J&J (1.24), Pfizer (1.36), Novartis (1.56) and Sanofi-Aventis (2.42).
Such “ear-on-ground” knowledge of the big five pharma drug portfolios has been carefully compiled in this study by independent assessment of investment worth based on an unbiased analyst pool.
The Who, What, Where, How and Why of this Report
Table 1: Which Top Five Global Pharma are Chosen?
Chart 1: Net Income per Employee against R&D Expenditures
Johnson & Johnson Case Study
Table 2: J&J’s New Medical Entity Filings 2007-2010
Pfizer Case Study
Table 3: Pfizer’s New Medical Entity Filings 2010 and Beyond
GlaxoSmithKline Case Study
Table 4: Sales & Success Estimates for GSK’s Early Phase-Clinically Superior Pipeline
Novartis Case Study
Table 5: Novartis’ Scheduled NME Filings from 2008 to Beyond 2011
Sanofi-Aventis Case Study
Table 6: Sanofi-Aventis’ Short-Term NME Filings
Table 7: PEG Ratio Valuation
Chart 2: PEG Ratio Valuation
Table 8: BCG Analysis
Chart 3: BCG Matrix of Global Pharma
Interpretation of BCG Matrix (Chart 3)
Appendix - Financial Terminology